Biolitec Says Sales May Increase 35% on U.S. Demand for Lasers

Dec. 5 (Bloomberg) -- Biolitec AG, the German company whose prostate-therapy laser was approved in the U.S. in 2007, expects revenue to rise as much as 35 percent this year, Chief Executive Officer Wolfgang Neuberger said.
``We expect a growth rate of 30 percent or maybe 35 percent'' this fiscal year, Neuberger said in a telephone interview Nov. 30. Sales at Jena, Germany-based company rose 34 percent to 39 million euros ($57.5 million) in the year ended June 30.
North American sales accounted for 52 percent of Biolitec revenue in the year ended in June, compared with 42 percent a year earlier, as U.S. demand for cosmetic and medical lasers increased. The German company has 20 percent of the U.S. market for prostate laser therapy and aims to have 40 percent by the end of 2008, Neuberger said.
Biolitec's lasers for prostate treatment vaporize enlarged tissue, while their heat cauterizes blood vessels to stem bleeding.

read the full article>> http://www.bloomberg.com/apps/news?pid=20601085&sid=adlbE4zMUciY&refer=europe